M
MYMD
vs
S&P 500
S&P 500
Over the past 12 months, MYMD has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +14% growth.
Stocks Performance
MYMD vs S&P 500
Performance Gap
MYMD vs S&P 500
Performance By Year
MYMD vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
MyMD Pharmaceuticals Inc
Glance View
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. The company is headquartered in Baltimore, Maryland and currently employs 9 full-time employees. The company went IPO on 2008-07-24. The firm is focused on developing and commercializing two therapeutic platforms based on therapeutic targets, MYMD-1 and Supera-CBD. MYMD-1 is a clinical-stage small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. MYMD-1 is being developed to treat age-related illnesses, such as frailty and sarcopenia. MYMD-1 works by regulating the release of numerous pro-inflammatory cytokines, such as TNF-a, interleukin 6 (IL-6) and interleukin 17 (IL-17). Supera-CBD is a synthetic analog of cannabidiol (CBD) being developed to treat various conditions, including epilepsy, pain and anxiety/depression, through its effects on the CB2 receptor, opioid receptors and monoamine oxidase enzyme (MAO) type B. Supera-CBD is also used in treating neuroinflammatory and neurodegenerative diseases.
